Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer
Main finding · VAT areaResult — go to the resultMean adjusted difference −5.00 cm² CI −16.9 to 6.91Authors' conclusion
These data provide reassurance that over the initial 12 months of AI therapy, AI treatment is not associated with metabolically adverse changes in body composition, hepatic steatosis or vascular reactivity. The impact of extended AI therapy on cardiometabolic health requires further study.
Study context
- Population
- Postmenopausal women with early and locally advanced oestrogen receptor-positive breast cancer; body composition by dual X-ray absorptiometry at baseline, 6 and 12 months
- Participants
- 52 vs 52
- Exposure
- Aromatase inhibitor (AI) initiation vs breast pathology not requiring endocrine therapy
- AIn = 52
- Controlsn = 52reference
- Outcome
- VAT area
- Follow-up
- 12 months
Main finding
As reported in the abstract
Mean adjusted difference
−5.00 cm²
CI −16.9 to 6.91
P = 0.55
Observational data: associations, not effects.
Further findings
Changes in total fat mass, lean mass, subcutaneous adipose tissue area, hepatic steatosis and endothelial function · 12 months
- Not statistically different between groups
Visceral adipose tissue (VAT) area, adjusted for activity levels and COVID lockdown duration · 12 months
- Findings were similar after adjustments
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →